Keyphrases
Chemotherapy
100%
Systemic Therapy
100%
Molecular Targeted Agents
100%
Salivary Gland Cancer
100%
Human Epidermal Growth Factor Receptor 2 (HER2)
66%
Response Rate
66%
Duration of Response
66%
Salivary Gland Malignancy
66%
Vascular Endothelial Growth Factor
33%
Well-defined
33%
Overexpression
33%
Tumor
33%
Molecular Markers
33%
Putative Drug Targets
33%
Poor Prognosis
33%
Metastatic Disease
33%
Head-and-neck Cancer
33%
Oncoprotein
33%
Conventional Chemotherapy
33%
All Cancer
33%
Recurrent Disease
33%
Initial Management
33%
Acinar Cells
33%
Poor Clinical Outcomes
33%
ErbB2
33%
Aggressiveness
33%
Small Sample Size
33%
Prognostic Significance
33%
P53 Protein
33%
Molecular Targeted Therapy
33%
Investigational Drugs
33%
Distinct Subtypes
33%
Clinical Behavior
33%
Adjuvant Radiation Therapy
33%
Adenocarcinoma
33%
Single-agent Chemotherapy
33%
Objective Response Rate
33%
Suboptimal Response
33%
Combination Chemotherapy
33%
Cytotoxic Agents
33%
ErbB1
33%
Head-and-neck Region
33%
Resectability
33%
Rare Malignancy
33%
Established Drugs
33%
Salivary Gland Tumor
33%
New Indication
33%
Mutated p53
33%
Locoregional Recurrence
33%
Epidermal Growth Factor Receptor Family
33%
EGFR Overexpression
33%
Salivary Duct
33%
Adenoid Cystic
33%
Mucoepidermoid
33%
Medicine and Dentistry
Systemic Therapy
100%
Salivary Gland Cancer
100%
Cancer
100%
Epidermal Growth Factor Receptor
80%
Salivary Gland
40%
Neoplasm
20%
Recurrent Disease
20%
Receptor Family
20%
Metastatic Carcinoma
20%
Adenocarcinoma
20%
Vasculotropin
20%
Protein P53
20%
Prognostication
20%
Epidermal Growth Factor Receptor 2
20%
Combination Chemotherapy
20%
Molecularly Targeted Therapy
20%
Salivary Gland Neoplasm
20%
Investigational Drug
20%
Neck
20%
Parotid Duct
20%
Diseases
20%
Radiation Therapy
20%
Molecular Marker
20%
Cytotoxic Agent
20%